JP Morgan upgraded Ionis Pharmaceuticals (NASDAQ:IONS) to overweight from neutral citing a potential label expansion for Tryngolza (olezarsen) and promising candidates in its pipeline. The bank raised its price target to $80 from $49 (~16% upside based on Oct. 7 close). ...